ContraMed Announces New Patent for Intrauterine Fallopian Tube Occlusion Device
3/9/2010 2:41:26 PM
CHARLOTTE, NC – ContraMed LLC is pleased to announce that it has received U.S. Patent No. 7,621,276 Intrauterine Fallopian Tube Occlusion Device which covers the Company’s methods for delivering an occlusion device for actively occluding the orifices of fallopian tubes. This technology allows for a single in-office minimally invasive surgical procedure. This patent also allows for the device to deliver medication or therapeutic agents to the uterine cavity.
ContraMed is also pleased to announce that is has received a Notice of Allowance for US patent application 11/884,027 INTRAUTERINE FALLOPIAN TUBE OCCLUSION DEVICE AND METHOD FOR USE which covers an occlusion device for actively occluding the orifices of the fallopian tubes using the shape of the uterine cavity as a guide.
“Today’s announcement broadens our current expansive patent portfolio covering a unique device that can be used as a tubal occlusion product and/or an intra-uterine device (IUD). Our technology is designed to be less invasive than the other available tubal occlusion products and to be non hormonal and not be made of copper from an IUD perspective,” said Michael Sinsheimer, President of ContraMed, LLC.
Beyond the newly announced intellectual property, ContraMed has tested its proprietary devices with impressive pilot clinical study results.
Steven R Goldstein, M.D., Professor of Obstetrics and Gynecology at New York University Langone Medical Center, said “The ContraMed device will revolutionize contraception by making it less invasive and more women friendly. It will provide non-hormonal contraception which eliminates the risk of hormonal side effects. Initial clinical studies show great promise."
ContraMed, LLC is an early-stage company that was founded to develop novel contraceptive devices which are intended to dramatically change the paradigm of sterilization and intra-uterine devices by being minimally invasive and inserted on an outpatient basis. The Company’s technology has been exclusively licensed from Yale University and is based on the inventions of Dr. Michael Tal of Yale University. Dr. Tal is a co-founder of ContraMed along with MedTech Catalyst and Yale University.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties ContraMed assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.
comments powered by